Literature DB >> 25573538

Pharmacological management of behavioral and psychiatric symptoms in older adults with intellectual disability.

Nicole Eady1, Ken Courtenay, André Strydom.   

Abstract

Given medical and social advances, the life expectancy of individuals with intellectual disability (ID) has increased dramatically, leading to a generation of older individuals with such disabilities. This review focuses on the pharmacological treatment of behavioral and psychiatric symptoms and disorders in older adults with ID. Older adults with ID often present with medical co-morbidities and mental health issues. Medication management of behavioral and psychiatric problems is complicated by a higher risk for adverse events, lack of decision-making capacity, and complex care networks. Some studies have shown that individuals with ID and co-morbid mental disorders are undertreated in comparison with those with similar disorders in the general population, resulting in poorer outcomes. However, older adults with ID are also at risk of polypharmacy, and older age is a risk factor for development of side effects. A general principle is that medication treatment for psychiatric disorders in older individuals with ID should be started at low dosages and increased cautiously while monitoring response and side effects. The use of psychotropic drugs for older individuals with ID and behavioral problems remains controversial, particularly in those with dementia.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25573538     DOI: 10.1007/s40266-014-0236-7

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  38 in total

1.  International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities.

Authors:  Shoumitro Deb; Henry Kwok; Marco Bertelli; Luis Salvador-Carulla; Elspeth Bradley; Jennifer Torr; Jarret Barnhill
Journal:  World Psychiatry       Date:  2009-10       Impact factor: 49.548

Review 2.  Dementia in intellectual disability.

Authors:  Rory Sheehan; Afia Ali; Angela Hassiotis
Journal:  Curr Opin Psychiatry       Date:  2014-03       Impact factor: 4.741

Review 3.  Prevalence of intellectual disability: a meta-analysis of population-based studies.

Authors:  Pallab K Maulik; Maya N Mascarenhas; Colin D Mathers; Tarun Dua; Shekhar Saxena
Journal:  Res Dev Disabil       Date:  2011-01-13

4.  Rivastigmine transdermal patches in the treatment of dementia in Alzheimer's disease in adults with Down syndrome-pilot study.

Authors:  V P Prasher; N Sachdeva; C Adams; M S Haque
Journal:  Int J Geriatr Psychiatry       Date:  2013-02       Impact factor: 3.485

5.  Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study.

Authors:  John A Tsiouris; Soh-Yule Kim; W Ted Brown; Jill Pettinger; Ira L Cohen
Journal:  J Autism Dev Disord       Date:  2013-03

Review 6.  Guidelines for the use of clozapine in individuals with developmental disabilities.

Authors:  Mohamed Sabaawi; Nirbhay N Singh; Jose de Leon
Journal:  Res Dev Disabil       Date:  2005-07-22

Review 7.  Melatonin and sleep disorders associated with intellectual disability: a clinical review.

Authors:  S G Sajith; D Clarke
Journal:  J Intellect Disabil Res       Date:  2007-01

8.  EFNS guidelines for the diagnosis and management of Alzheimer's disease.

Authors:  J Hort; J T O'Brien; G Gainotti; T Pirttila; B O Popescu; I Rektorova; S Sorbi; P Scheltens
Journal:  Eur J Neurol       Date:  2010-10       Impact factor: 6.089

Review 9.  The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

Authors:  M Bond; G Rogers; J Peters; R Anderson; M Hoyle; A Miners; T Moxham; S Davis; P Thokala; A Wailoo; M Jeffreys; C Hyde
Journal:  Health Technol Assess       Date:  2012       Impact factor: 4.014

10.  Psychotropic prescribing for persons with intellectual disabilities and other psychiatric disorders.

Authors:  Gail A Edelsohn; James M Schuster; Kim Castelnovo; Lauren Terhorst; Meghna Parthasarathy
Journal:  Psychiatr Serv       Date:  2014-02-01       Impact factor: 3.084

View more
  7 in total

1.  Primary care of adults with intellectual and developmental disabilities: 2018 Canadian consensus guidelines.

Authors:  William F Sullivan; Heidi Diepstra; John Heng; Shara Ally; Elspeth Bradley; Ian Casson; Brian Hennen; Maureen Kelly; Marika Korossy; Karen McNeil; Dara Abells; Khush Amaria; Kerry Boyd; Meg Gemmill; Elizabeth Grier; Natalie Kennie-Kaulbach; Mackenzie Ketchell; Jessica Ladouceur; Amanda Lepp; Yona Lunsky; Shirley McMillan; Ullanda Niel; Samantha Sacks; Sarah Shea; Katherine Stringer; Kyle Sue; Sandra Witherbee
Journal:  Can Fam Physician       Date:  2018-04       Impact factor: 3.275

2. 

Authors:  William F Sullivan; Heidi Diepstra; John Heng; Shara Ally; Elspeth Bradley; Ian Casson; Brian Hennen; Maureen Kelly; Marika Korossy; Karen McNeil; Dara Abells; Khush Amaria; Kerry Boyd; Meg Gemmill; Elizabeth Grier; Natalie Kennie-Kaulbach; Mackenzie Ketchell; Jessica Ladouceur; Amanda Lepp; Yona Lunsky; Shirley McMillan; Ullanda Niel; Samantha Sacks; Sarah Shea; Katherine Stringer; Kyle Sue; Sandra Witherbee
Journal:  Can Fam Physician       Date:  2018-04       Impact factor: 3.275

3.  Management of psychotropic medications in adults with intellectual disability: a scoping review.

Authors:  Ashley Costello; Eithne Hudson; Susan Morrissey; Drona Sharma; Dervla Kelly; Owen Doody
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

4.  Psychotropic drugs intake in people aging with intellectual disability: Prevalence and predictors.

Authors:  Laura García-Domínguez; Patricia Navas; Miguel Ángel Verdugo; Víctor B Arias; Laura E Gómez
Journal:  J Appl Res Intellect Disabil       Date:  2022-04-05

5.  Prescription of potentially inappropriate medications among older people with intellectual disability: a register study.

Authors:  Anna Axmon; Magnus Sandberg; Gerd Ahlström; Patrik Midlöv
Journal:  BMC Pharmacol Toxicol       Date:  2017-10-25       Impact factor: 2.483

6.  Anticholinergic burden in adult and elderly people with intellectual disabilities: Results from an Italian multicenter cross-sectional study.

Authors:  Luc Pieter De Vreese; Ulrico Mantesso; Elisa De Bastiani; Annachiara Marangoni; Elisabeth Weger; Tiziano Gomiero
Journal:  PLoS One       Date:  2018-10-31       Impact factor: 3.240

Review 7.  Neurobiology of ARID1B haploinsufficiency related to neurodevelopmental and psychiatric disorders.

Authors:  Jeffrey J Moffat; Amanda L Smith; Eui-Man Jung; Minhan Ka; Woo-Yang Kim
Journal:  Mol Psychiatry       Date:  2021-03-08       Impact factor: 15.992

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.